Product Development

June 29, 2018

Notes From the Field – The Drug/Device Combination Product Summit

We recently had the opportunity to speak at the Combination Product Life Cycle Management Summit, which was held in Boston earlier this month. Our co-founder and COO, Phil Burke, presented best practices for developing a dedicated, medical device designed to deliver a therapeutic drug. In attendance were quality, regulatory and device strategy/management professionals from a veritable Who’s Who of Big Pharma. The drug/device combination products market is, in many ways, still relatively nascent. It’s also […]
April 25, 2018
REV.1 Engineering Medical Device Development Team

The Strategic Risk of Engineering Talent Turnover

Do You Have Contingencies in Place to Counter Disruption from the Coming Talent Wars? It’s a topic that’s been front and center since our recovery from the Great Recession: How will companies that depend on knowledge workers for value creation react to the inevitable talent wars? Due to the growing complexity and sophistication of our products, perhaps no other segment is more vulnerable to disruption than the medical device industry. And perhaps no place is […]
April 12, 2018
Internal Drug Delivery Device

De-Risking the Development of Drug/Device Combination Products

Navigating the Critical Path with Combination Products A market research study, published earlier this week by Market.Biz, illustrates the promise of what is perhaps the most dynamic technology segment emerging in healthcare; combination products. The research pegged the value of the combination products market at $64.7 billion in 2017, and projects a CAGR (current annual growth rate) of 13.8% through 2023, escalating the market value to a staggering $94.5 billion by that time. One of […]
March 29, 2018

Strategic Risk Management in Medical Device Development and Innovation

Employing Clinical Pathway Impact Analysis™ to drive efficacy at launch. While large medical device corporations have long looked to startups for new technologies and devices, there are additional, innovative benefits woven into the fabric of these nimble firms. Startups that survive long enough to deliver commercial assets must first survive a form of natural selection. A similar process can benefit any new device development project. At each stage of organizational progression, from seed funding to […]
X
Schedule a Conversation
Contact Us